Compare C3.ai Inc (AI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C3.ai Inc vs Sanofi SA — how do they compare? C3.ai Inc trades at $10.17 (market cap $1.57B), while Sanofi SA trades at $43.91 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 66.4× C3.ai Inc's market cap, and Sanofi SA pays a 5.53% dividend while C3.ai Inc pays none. Which is the better fit depends on your goals.
| AI | SNY | |
|---|---|---|
Market Cap | $1.57B | $104.30B |
Sector | Technology | Health |
52-Week High | $19.66 | $52.34 |
52-Week Low | $7.76 | $41.33 |
Enterprise Value | $997.06M | $124.19B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai (AI) trades at $10.18, down 4.23% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company shows revenue growth to $389M in 2025 but continues significant losses with a -187.95% net income margin. Recent positive news includes being named a Leader in AI Platforms by Forrester Research (Business Wire, August 10, 2026).
The stock presents a high-risk opportunity with Wall Street divided - 21% buy ratings versus 25% sell. While revenue growth and industry recognition are positive, persistent losses and negative cash flow pose substantial risks. The consensus price target of $10.20 suggests limited near-term upside from current levels.
SNY trades at $43.78, up 0.51% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales outlook. Revenue for 2025 was $46.72 billion, with net income of $7.81 billion, reflecting a profit margin of 16.72%. Key growth driver Dupixent surpassed €5 billion in quarterly sales, supporting positive sentiment amid pipeline adjustments under new CEO Belen Garijo.
SNY presents a mixed outlook with solid fundamentals and recent earnings beats offset by pipeline setbacks and competitive risks. The stock's valuation metrics, including a P/E of 23.38 and P/S of 1.88, appear reasonable relative to peers. However, investors face risks from biosimilar threats to Dupixent post-2031 and regulatory scrutiny. Analyst consensus leans neutral with 44% buy ratings, suggesting cautious optimism for upside potential driven by execution on new drug launches and cost discipline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
